Evaluating the post-licensure effectiveness of a group B meningococcal vaccine in New Zealand: a multi-faceted strategy

Vaccine. 2005 Mar 18;23(17-18):2231-4. doi: 10.1016/j.vaccine.2005.01.048.

Abstract

A nationwide strategy to control a group B meningococcal disease epidemic in New Zealand using an epidemic strain-specific vaccine (MeNZB ) commenced in 2004. In the absence of randomised controlled trials investigating the efficacy of this particular vaccine, a complement of observational methods are planned to evaluate the post-licensure effectiveness of this vaccine strategy. The two main approaches involve a Poisson regression model investigating the overall impact of the MeNZB programme on disease rates over time capitalising on detailed population-based disease surveillance data and the staged roll-out of the vaccine campaign, and a case-control study that aims to estimate vaccine effectiveness in pre-school children. The studies are designed to minimise the potential biases inherent in all observational methods and provide critical data on the effectiveness of a major public health intervention.

Publication types

  • Evaluation Study

MeSH terms

  • Adolescent
  • Adult
  • Bacterial Vaccines / pharmacology*
  • Case-Control Studies
  • Child
  • Child, Preschool
  • Disease Outbreaks / prevention & control
  • Humans
  • Infant
  • Infant, Newborn
  • Meningococcal Infections / epidemiology
  • Meningococcal Infections / prevention & control*
  • National Health Programs
  • Neisseria meningitidis, Serogroup B*
  • New Zealand / epidemiology
  • Poisson Distribution

Substances

  • Bacterial Vaccines